KEI and UACT comments on the prospective grant of exclusive licenses to Sinotau and MTTI

On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading

Biolyse Pharma offers to supply enzalutamide (Xtandi) for $3 per pill to Medicare and developing countries

On April 22, 2016, the President of Biolyse Pharma — a Canadian pharmaceutical company that specializes in the manufacture of oncology drugs — offered to supply the prostate cancer drug enzalutamide (Xtandi) to the Centers for Medicare & Medicaid Services (CMS) for $3 per pill ($12 per day; $4,383 per year). The Biolyse price for enzalutamide is 4-percent of the 2014 Medicare price, $69.41 ($277.64 per day; $101,408.01 per year), and lower than any other price in the world.

Continue Reading

2016: Midissia Therapeutics license of NIH owned breast and prostate cancer vaccine patents

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Sabarni K. Chatterjee, Ph.D., M.B.A. Senior Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702… Continue Reading

Xtandi 2016 March-In Request

Today Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) petitioned the Department of Health and Human Services, the Department of Defense, and the National Institutes of Health, asking that they exercise either their royalty-free, non-exclusive license or federal “march-in” rights to end the monopoly on an expensive prostate cancer drug, enzalutamide, marketed as Xtandi by Astellas, a Japanese pharmaceutical company.

Xtandi was invented at UCLA on federal grants from the NIH and DoD.

Continue Reading